COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)

Azienda Ospedaliera San Paolo

Status: Unknown

Conditions: COVID-19

Treatments: Other: BioMedomics COVID-19 IgM-IgG Rapid Test

Study type: Observational

Funder types: Other

Identifiers

NCT04367402

2020/ST/057

Details and patient eligibility

About

The aims of this study is to define the genetic bases of COVID-19 related disease heterogeneity in frail population, to carry out a retrospective study on individuals w/wo symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis and on the presence of genetic profiling and to explore the therapeutic potential of the modulation of ACE2 expression.

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• adult patients (> 18 years old)

Exclusion criteria

• inability to understand and want;
• mentally incapacitated.

Trial design

600 participants in 3 patient groups

Symptomatic Patients

Description:

Patients who had symptoms related to COVID-19 infection

Treatment:

Other: BioMedomics COVID-19 IgM-IgG Rapid Test

Health people

Description:

Healthy people who never had syntomps related to COVID-19 infection

Treatment:

Other: BioMedomics COVID-19 IgM-IgG Rapid Test

Asyntomatic Individuals

Description:

Asyntomatic people to recruit after the restriction have ended

Treatment:

Other: BioMedomics COVID-19 IgM-IgG Rapid Test